Physiologic Assessment of Microvascular Function in Heart Transplant Patients
Launched by SAMSUNG MEDICAL CENTER · Jun 9, 2016
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well the tiny blood vessels in the heart function in people who have received a heart transplant. Specifically, the study aims to see if early signs of microvascular disease, which can be measured using certain tests, can help predict the risk of developing a condition called cardiac allograft vasculopathy (CAV) in heart transplant patients. CAV is a serious complication that can affect the transplanted heart.
To participate in this study, individuals must be over 18 years old and have received a heart transplant. However, those with severe heart problems or bleeding issues, among other health concerns, will not be eligible. If you join the trial, you can expect to undergo tests that measure blood flow in your heart, which will help researchers understand the health of your heart's small blood vessels. This information could be important for improving care and outcomes for heart transplant recipients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject over age of 18
- • Patients received heart transplant
- Exclusion Criteria:
- • Patients with cardiogenic shock
- • Patients with unstable vital sign that precludes coronary angiography
- • Patients with major bleeding in last 3 months
- • Patients with active bleeding
- • Patients with coagulopathy
- • Patients with severe valvular heart disease
- • Patients who refused to provide informed consent
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Joo Myung Lee, MD, MPH
Principal Investigator
Samsung Medical Center
Jin-Oh Choi, MD, PhD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials